Patients treated in an outpatient setting who later required admission spent an average of 12.1 days in the hospital, ...

The EVEREST-2 study reported the first complete response to CAR-T cell therapy in a non-small cell lung cancer patient. A2B694 therapy was well tolerated, showing no dose-limiting toxicities and ...

Wang also acknowledges emerging platforms such as CAR NK cells and in vivo CAR T technologies but notes these remain ...

Next-generation automation is closing the gap between curative science and real-world demand, enabling faster development, ...

Autolus Therapeutics is working with Cellares to assess automated CAR T manufacturing to support rising demand for its ...

CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing ...

Improved QOL is observed in patients over two years post-infusion and those without disease progression, highlighting the ...

CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has revolutionized how physicians treat cancer, especially blood cancers. “These patients can be cured ...

As demand for precision medicine accelerates, CAR T and CAR Treg cell therapies are emerging as crucial tools in the fight against cancer and autoimmune diseases. For Thomas Fellner, PhD, head of ...